Elevated expression of CXC chemokines in pediatric osteosarcoma patients

Cancer

Volumn 117, Issue 1, 2011, Pages 207-217

  Li, Yiting ^a,b   Flores, Ricardo ^a,b   Yu, Alexander ^a,b   Okcu, M Fatih ^a,b   Murray, Jeffrey ^c   Chintagumpala, Murali ^a,b   Hicks, John ^b   Lau, Ching C ^a,b   Man, Tsz Kwong ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Cook Children's Medical Center ^*  (United States)

Author keywords

antibody microarray; biomarkers; cell proliferation; CXC chemokines; osteosarcoma

Indexed keywords

ALPHA CHEMOKINE; CXCL4 CHEMOKINE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; TISSUE MICROARRAY; VALIDATION PROCESS;

ADOLESCENT; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; CHEMOKINE CXCL6; CHEMOKINES, CXC; CHILD; FEMALE; HUMANS; MALE; OSTEOSARCOMA; PLATELET FACTOR 4; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650715738     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25563     Document Type: Article

References (42)

1. Huvos A,. Bone Tumors: Diagnosis, Treatment and Prognosis. Philadelphia, PA: WB Saunders; 1991.
2. Dahlin DC, Unni K,. Bone Tumors: General Aspects and Data on 8542 Cases. Springfield, IL: Charles C. Thomas; 1986.
3. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003; 14: 1126-1134.
4. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003; 21: 2011-2018.
5. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-1238.
6. Matsunaga E,. Hereditary retinoblastoma: host resistance and second primary tumors. J Natl Cancer Inst. 1980; 65: 47-51.
7. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003; 95: 669-674.
8. Laing KJ, Secombes CJ,. Chemokines. Dev Comp Immunol. 2004; 28: 443-460.
9. Fernandez EJ, Lolis E,. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002; 42: 469-499.
10. Vandercappellen J, Van DJ, Struyf S,. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267: 226-244.
11. Wu X, Lee VC, Chevalier E, Hwang ST,. Chemokine receptors as targets for cancer therapy. Curr Pharm Des. 2009; 15: 742-757.
12. Vandercappellen J, Van DJ, Struyf S,. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267: 226-244.
13. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA,. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006; 42: 768-778.
14. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 2005; 11: 490-497.
15. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008; 25: 201-211.
16. Sun L, Chen C,. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem. 1997; 272: 25367-25372.
17. Maliekal TT, Antony ML, Nair A, Paulmurugan R, Karunagaran D,. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene. 2003; 22: 4889-4897.
18. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001; 20: 4621-4628.
19. Matsunaga E,. Hereditary retinoblastoma: host resistance and second primary tumors. J Natl Cancer Inst. 1980; 65: 47-51.
20. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003; 95: 669-674.
21. Di RP, Benedetti PP, Scambia G, et al. Early hemostatic disorders in patients with gynecologic tumors. Eur J Gynaecol Oncol. 1986; 7: 109-112.
22. Landolfi R, Storti S, Sacco F, Scribano D, Cudillo L, Leone G,. Platelet activation in patients with benign and malignant ovarian diseases. Tumori. 1984; 70: 459-462.
23. Al-Mondhiry H, Manni A, Owen J, Gordon R,. Hemostatic effects of hormonal stimulation in patients with metastatic prostate cancer. Am J Hematol. 1988; 28: 141-145.
24. von HP, Petersen F, Brandt E,. Platelet-derived chemokines in vascular biology. Thromb Haemost. 2007; 97: 704-713.
25. Al-Mondhiry H,. beta-Thromboglobulin and platelet-factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy. Am J Hematol. 1983; 14: 105-111.
26. Strieter RM, Polverini PJ, Arenberg DA, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol. 1995; 57: 752-762.
27. Yamaguchi K, Ogawa K, Katsube T, et al. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res. 2005; 25: 847-851.
28. Proost P, De Wolf-Peeters C, Conings R, Opdenakker G, Billiau A, Van DJ,. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J Immunol. 1993; 150: 1000-1010.
29. Lazzeri E, Romagnani P,. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord. 2005; 5: 109-118.
30. Luker KE, Luker GD,. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006; 238: 30-41.
31. Gelmini S, Mangoni M, Serio M, Romagnani P, Lazzeri E,. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J Endocrinol Invest. 2008; 31: 809-819.
32. Kryczek I, Wei S, Keller E, Liu R, Zou W,. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol. 2007; 292: C987-C995.
33. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 2005; 11: 490-497.
34. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006; 19: 738-745.
35. Luker KE, Luker GD,. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006; 238: 30-41.
36. Cervi D, Yip TT, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2008; 111: 1201-1207.
37. Zhu YM, Bagstaff SM, Woll PJ,. Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer. Br J Cancer. 2006; 94: 1936-1941.
38. Van CE, Van A, I, Wuyts A, et al. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. Am J Pathol. 2001; 159: 1405-1414.
39. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002; 62: 5930-5938.
40. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1. J Biol Chem. 2005; 280: 22473-22481.
41. von Luettichau I, Segerer S, Wechselberger A, et al. A complex pattern of chemokine receptor expression is seen in osteosarcoma. BMC Cancer. 2008; 8: 23.
42. Lavrovsky Y, Ivanenkov YA, Balakin KV, Medvedeva DA, Ivachtchenko AV,. CXCR4 receptor as a promising target for oncolytic drugs. Mini Rev Med Chem. 2008; 8: 1075-1087.